These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 21756081

  • 1. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
    Koiou E, Tziomalos K, Katsikis I, Kandaraki EA, Kalaitzakis E, Delkos D, Vosnakis C, Panidis D.
    Gynecol Endocrinol; 2012 Jan; 28(1):20-4. PubMed ID: 21756081
    [Abstract] [Full Text] [Related]

  • 2. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
    Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Katsikis I.
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):432-8. PubMed ID: 23909452
    [Abstract] [Full Text] [Related]

  • 3. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D.
    Hormones (Athens); 2013 Mar; 12(4):559-66. PubMed ID: 24457404
    [Abstract] [Full Text] [Related]

  • 4. The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study.
    Panidis D, Tziomalos K, Koiou E, Kandaraki EA, Tsourdi E, Delkos D, Kalaitzakis E, Katsikis I.
    Reprod Biol Endocrinol; 2010 Dec 09; 8():151. PubMed ID: 21143924
    [Abstract] [Full Text] [Related]

  • 5. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
    Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, Delkos D, Kandaraki EA, Panidis D.
    Endocr J; 2011 Dec 09; 58(4):237-46. PubMed ID: 21325745
    [Abstract] [Full Text] [Related]

  • 6. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
    Vosnakis C, Georgopoulos NA, Rousso D, Mavromatidis G, Katsikis I, Roupas ND, Mamali I, Panidis D.
    Gynecol Endocrinol; 2013 Mar 09; 29(3):242-5. PubMed ID: 23194076
    [Abstract] [Full Text] [Related]

  • 7. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 09; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 8. Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
    Vosnakis C, Georgopoulos NA, Armeni AK, Papadakis E, Roupas ND, Katsikis I, Panidis D.
    Eur J Obstet Gynecol Reprod Biol; 2012 Aug 09; 163(2):185-9. PubMed ID: 22579228
    [Abstract] [Full Text] [Related]

  • 9. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.
    Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, Tsourdi E, Panidis D.
    Obes Facts; 2012 Aug 09; 5(4):495-504. PubMed ID: 22854419
    [Abstract] [Full Text] [Related]

  • 10. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?
    Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I.
    Eur J Endocrinol; 2008 Apr 09; 158(4):525-31. PubMed ID: 18362300
    [Abstract] [Full Text] [Related]

  • 11. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr 09; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 12. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome.
    Cengiz H, Ekin M, Dagdeviren H, Yildiz Ş, Kaya C, Kanawati A.
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep 09; 180():46-50. PubMed ID: 25036408
    [Abstract] [Full Text] [Related]

  • 13. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.
    Ravn P, Haugen AG, Glintborg D.
    Minerva Endocrinol; 2013 Mar 09; 38(1):59-76. PubMed ID: 23435443
    [Abstract] [Full Text] [Related]

  • 14. [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
    Le Donne M, Alibrandi A, Giarrusso R, Lo Monaco I, Muraca U.
    Minerva Ginecol; 2012 Feb 09; 64(1):23-9. PubMed ID: 22334228
    [Abstract] [Full Text] [Related]

  • 15. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D.
    Clin Endocrinol (Oxf); 2007 Jan 09; 66(1):103-9. PubMed ID: 17201808
    [Abstract] [Full Text] [Related]

  • 16. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO.
    Gynecol Endocrinol; 2018 May 09; 34(5):413-417. PubMed ID: 29172796
    [Abstract] [Full Text] [Related]

  • 17. Serum antimüllerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial.
    Nybacka Å, Carlström K, Fabri F, Hellström PM, Hirschberg AL.
    Fertil Steril; 2013 Oct 09; 100(4):1096-102. PubMed ID: 23876536
    [Abstract] [Full Text] [Related]

  • 18. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug 09; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 19. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H, Yang G, Li L.
    J Clin Endocrinol Metab; 2015 Apr 09; 100(4):1485-93. PubMed ID: 25675380
    [Abstract] [Full Text] [Related]

  • 20. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F, Zamani MM, Heshmat R, Moini nia F.
    J Obstet Gynaecol Res; 2013 Apr 09; 39(4):806-13. PubMed ID: 23279603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.